Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 875 of 3499 entries
View as:

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Phase: N/A Priority: Normal
NCT ID: NCT01041638 Org: User:
Start: 12/21/09 End: 06/30/21 Due: 06/30/22

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT01922076 Org: User:
Start: 09/03/13 End: 09/30/22 Due: 09/30/23

Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s

Phase: N/A Priority: Normal
NCT ID: NCT04488263 Org: User:
Start: 11/24/20 End: 01/11/23 Due: 01/11/24

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04576091 Org: User:
Start: 07/06/22 End: 12/11/25 Due: 12/11/26

Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00062127 Org: User:
Start: 04/30/03 End: - Due: -

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04216316 Org: User:
Start: 04/14/21 End: 04/12/25 Due: 04/12/26

Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy

Phase: N/A Priority: Normal
NCT ID: NCT00001387 Org: User:
Start: 09/30/94 End: 07/31/00 Due: 07/31/01

SU5416 and Carboplatin to Treat Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00006155 Org: User:
Start: 08/31/00 End: 04/30/01 Due: 04/30/02

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00381940 Org: User:
Start: 01/31/07 End: 12/31/16 Due: 12/31/17

A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT00036569 Org: User:
Start: 05/31/02 End: 01/31/12 Due: 01/31/13

FdCyd and THU for Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01534598 Org: User:
Start: 03/05/12 End: 02/19/20 Due: 02/19/21

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Phase: N/A Priority: Normal
NCT ID: NCT04269902 Org: User:
Start: 03/02/21 End: 10/01/28 Due: 10/01/29

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Phase: N/A Priority: Normal
NCT ID: NCT06041503 Org: User:
Start: 07/02/25 End: 10/01/28 Due: 10/01/29

Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia

Phase: N/A Priority: Normal
NCT ID: NCT06744283 Org: User:
Start: 07/02/25 End: 01/30/26 Due: 01/30/27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT06694454 Org: User:
Start: 07/02/25 End: 12/31/34 Due: 12/31/35

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Phase: N/A Priority: Normal
NCT ID: NCT04449549 Org: User:
Start: 08/24/20 End: 04/08/26 Due: 04/08/27

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00001163 Org: User:
Start: 04/02/85 End: - Due: -

FAU in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00769288 Org: User:
Start: 07/31/09 End: - Due: -

Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors

Phase: N/A Priority: Normal
NCT ID: NCT00001301 Org: User:
Start: 08/31/92 End: 04/30/00 Due: 04/30/01

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Phase: N/A Priority: Normal
NCT ID: NCT04576117 Org: User:
Start: 02/16/21 End: 12/30/26 Due: 12/30/27

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT05001880 Org: User:
Start: 03/22/22 End: 08/20/25 Due: 08/20/26

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Phase: N/A Priority: Normal
NCT ID: NCT06406465 Org: User:
Start: 07/02/25 End: 07/30/28 Due: 07/30/29

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Phase: N/A Priority: Normal
NCT ID: NCT05828069 Org: User:
Start: 03/28/24 End: 09/30/28 Due: 09/30/29

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Phase: N/A Priority: Normal
NCT ID: NCT05987241 Org: User:
Start: 02/02/24 End: 09/02/30 Due: 09/02/31

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Phase: N/A Priority: Normal
NCT ID: NCT05588141 Org: User:
Start: 05/16/23 End: 08/02/29 Due: 08/02/30